Signaling pathway factors expression in renal tissue of apoE-knockout mice

References

• Zhou TB. Signaling pathways of apoE and its role of gene expression in glomerulus diseases. J Recept Signal Transduct Res 2013;33:73–8
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH, Lei FY, et al. All-trans retinoic acid regulates the expression of apolipoprotein E in rats with glomerulosclerosis induced by Adriamycin. Exp Mol Pathol 2011;90:287–94
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH, Lei FY, et al. apoE expression in glomerulus and correlation with glomerulosclerosis induced by adriamycin in rats. Ren Fail 2011;33:348–54
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH, Lei FY, et al. Less gelatinases is associated with apolipoprotein E accumulation in glomerulosclerosis rats. Histol Histopathol 2012;27:249–56
   PubMed Web of Science ®Google Scholar
• Zhou TB, Qin YH, Ou C, et al. All-trans retinoic acid can regulate the expressions of gelatinases and apolipoprotein E in glomerulosclerosis rats. Vascul Pharmacol 2011;55:169–77
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu H, Huang Z, et al. Apolipoprotein E-knockout mice on high-fat diet show autoimmune injury on kidney and aorta. Biochem Biophys Res Commun 2014;450:788–93
   PubMed Web of Science ®Google Scholar
• Bruneval P, Bariety J, Belair MF, et al. Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 2002;17:2099–107
   PubMed Web of Science ®Google Scholar
• Moghadasian MH, McManus BM, Nguyen LB, et al. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. FASEB J 2001;15:2623–30
   PubMed Web of Science ®Google Scholar
• Jiang ZP, Zhou TB. Role of miR-107 and its signaling pathways in diseases. J Recept Signal Transduct Res 2014;34:338–41
   PubMed Web of Science ®Google Scholar
• Taibi F, Metzinger-Le Meuth V, M'Baya-Moutoula E, et al. Possible involvement of microRNAs in vascular damage in experimental chronic kidney disease. Biochim Biophys Acta 2014;1842:88–98
   PubMed Web of Science ®Google Scholar
• Rangrez AY, M'Baya-Moutoula E, Metzinger-Le Meuth V, et al. Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. PLoS One 2012;7:e47807
   PubMed Web of Science ®Google Scholar
• Suski M, Olszanecki R, Stachowicz A, et al. The influence of angiotensin-(1-7) Mas receptor agonist (AVE 0991) on mitochondrial proteome in kidneys of apoE knockout mice. Biochim Biophys Acta 2013;1834:2463–69
   PubMed Web of Science ®Google Scholar
• Stegbauer J, Potthoff SA, Quack I, et al. Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice. Br J Pharmacol 2011;163:974–83
   PubMed Web of Science ®Google Scholar
• Potthoff SA, Fahling M, Clasen T, et al. Angiotensin-(1-7) modulates renal vascular resistance through inhibition of p38 mitogen-activated protein kinase in apolipoprotein E-deficient mice. Hypertension 2014;63:265–72
   PubMed Web of Science ®Google Scholar
• Kawahito H, Yamada H, Irie D, et al. Periaortic adipose tissue-specific activation of the renin-angiotensin system contributes to atherosclerosis development in uninephrectomized apoE−/− mice. Am J Physiol Heart Circ Physiol 2013;305:H667–75
   PubMed Web of Science ®Google Scholar
• Kaliappan G, Nagarajan P, Moorthy R, et al. Ang II induce kidney damage by recruiting inflammatory cells and up regulates PPAR gamma and Renin 1 gene: effect of beta carotene on chronic renal damage. J Thromb Thrombolysis 2013;36:277–85
   PubMed Web of Science ®Google Scholar
• Li J, Guan M, Li C, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice. Int J Mol Sci 2014;15:11416–34
   PubMed Web of Science ®Google Scholar
• Wen M, Segerer S, Dantas M, et al. Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002;82:999–1006
   PubMed Web of Science ®Google Scholar
• Hone E, Martins IJ, Fonte J, Martins RN. Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 2003;5:1–8
   PubMedGoogle Scholar
• Arend N, Hilgers KF, Campean V, et al. Darbepoetin alpha reduces oxidative stress and chronic inflammation in atherosclerotic lesions of apo E deficient mice in experimental renal failure. PLoS One 2014;9:e88601
   PubMed Web of Science ®Google Scholar
• Yu J, Deng M, Zhao J, Huang L. Decreased expression of klotho gene in uremic atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 2010;391:261–66
   PubMed Web of Science ®Google Scholar
• Sastre C, Rubio-Navarro A, Buendia I, et al. Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice. PLoS One 2013;8:e83713
   PubMed Web of Science ®Google Scholar
• Diaz JA, Ballard-Lipka NE, Farris DM, et al. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. J Vasc Surg 2012;55:815–22
   PubMed Web of Science ®Google Scholar
• Stouffer GA, Pathak A, Rojas M. Unilateral renal artery stenosis causes a chronic vascular inflammatory response in ApoE−/− mice. Trans Am Clin Climatol Assoc 2010;121:252–64
   PubMedGoogle Scholar
• von zur Muhlen C, Schiffer E, Sackmann C, et al. Urine proteome analysis reflects atherosclerotic disease in an ApoE−/− mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics 2012;11: http://www.ncbi.nlm.nih.gov/pubmed/?term=22371488
   PubMed Web of Science ®Google Scholar
• Ge S, Hertel B, Koltsova EK, et al. Increased atherosclerotic lesion formation and vascular leukocyte accumulation in renal impairment are mediated by interleukin-17A. Circ Res 2013;113:965–74
   PubMed Web of Science ®Google Scholar
• Lassila M, Seah KK, Allen TJ, et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004;15:2125–38
   PubMed Web of Science ®Google Scholar
• Gut N, Piecha G, Pradel A, et al. The calcimimetic R-568 prevents podocyte loss in uninephrectomized ApoE−/− mice. Am J Physiol Renal Physiol 2013;305:F277–85
   PubMed Web of Science ®Google Scholar
• Zhang X, Urbieta-Caceres VH, Eirin A, et al. Humanin prevents intra-renal microvascular remodeling and inflammation in hypercholesterolemic ApoE deficient mice. Life Sci 2012;91:199–206
   PubMed Web of Science ®Google Scholar
• Watson AM, Gray SP, Jiaze L, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 2012;61:2105–13
   PubMed Web of Science ®Google Scholar
• Hayashi K, Sasamura H, Azegami T, Itoh H. Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. J Atheroscler Thromb 2012;19:736–46
   PubMed Web of Science ®Google Scholar
• Giunti S, Calkin AC, Forbes JM, et al. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol 2010;299:F528–35
   PubMed Web of Science ®Google Scholar
• Calkin AC, Giunti S, Jandeleit-Dahm KA, et al. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 2006;21:2399–405
   PubMed Web of Science ®Google Scholar
• Elitok S, Brodsky SV, Patschan D, et al. Cyclic arginine-glycine-aspartic acid peptide inhibits macrophage infiltration of the kidney and carotid artery lesions in apo-E-deficient mice. Am J Physiol Renal Physiol 2006;290:F159–66
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm K, Lassila M, Davis BJ, et al. Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. J Hypertens 2005;23:2071–82
   PubMed Web of Science ®Google Scholar
• Lassila M, Jandeleit-Dahm K, Seah KK, et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005;16:363–73
   PubMed Web of Science ®Google Scholar